Pomerantz LLP

Please review this complaint. Click to Contact Us about joining this ACTION >>

Questions? Ask Us

Acer Therapeutics Inc.

Pomerantz LLP is investigating claims on behalf of investors of Acer Therapeutics Inc. (''Acer'' or the ''Company'') (ACER). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Acer and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

On June 25, 2019, Acer disclosed receipt of a Complete Response Letter (''CRL'') from the U.S. Food and Drug Administration (''FDA'') regarding its marketing application for EDSIVO (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (''vEDS''). Acer advised investors that ''[t]he CRL states that it will be necessary to conduct an adequate and well-controlled trial to determine whether celiprolol reduces the risk of clinical events in patients with vEDS'' and that ''Acer plans to request a meeting to discuss the FDA's response.'' On this news, Acer's stock price fell sharply during intraday trading on June 25, 2019.